CJEU Advocate General recommends throwing out innovator-friendly Neurim decision
If the full court agrees with the opinion, which relates to the crucial Santen SPC case, it would limit the IP protection open to second medical use innovations in the EU
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.